Replimune Group, Inc. (NASDAQ:REPL) Receives $6.50 Consensus Target Price from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned an average recommendation of “Reduce” from the eleven ratings firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $6.50.

REPL has been the subject of a number of research reports. Leerink Partners reissued a “market perform” rating and set a $3.00 target price (down previously from $21.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. Barclays cut Replimune Group from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $17.00 to $3.00 in a research report on Wednesday, July 23rd. BMO Capital Markets cut Replimune Group from an “outperform” rating to an “underperform” rating and reduced their price objective for the company from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Wedbush reiterated a “neutral” rating and set a $4.00 price target (down from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Finally, Jefferies Financial Group reduced their price target on Replimune Group from $31.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd.

Insider Transactions at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of Replimune Group stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the sale, the chief financial officer directly owned 134,368 shares in the company, valued at $721,556.16. The trade was a 6.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System lifted its position in shares of Replimune Group by 25.9% in the fourth quarter. California State Teachers Retirement System now owns 42,725 shares of the company’s stock worth $517,000 after buying an additional 8,793 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Replimune Group by 897.2% in the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company’s stock worth $902,000 after buying an additional 7,913 shares during the last quarter. Moody Aldrich Partners LLC acquired a new stake in Replimune Group in the 1st quarter worth approximately $1,925,000. Bank of New York Mellon Corp lifted its holdings in Replimune Group by 8.4% in the 1st quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company’s stock worth $1,844,000 after purchasing an additional 14,659 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company’s stock worth $151,000 after purchasing an additional 2,545 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Performance

REPL stock opened at $4.65 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.94 and a current ratio of 6.94. The stock has a market cap of $362.98 million, a P/E ratio of -1.44 and a beta of 0.42. The firm has a 50 day simple moving average of $5.31 and a 200 day simple moving average of $7.57. Replimune Group has a 52 week low of $2.68 and a 52 week high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Research analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.